A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog; in Subjects With Type 1 Diabetes
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2017
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Dec 2012 Planned number of patients changed from 36 to 42 as reported by ClinicalTrials.gov.